Quartet Medicine Inc. CEO Kevin Pojasek told BioWorld Today that the finished series A round brought aboard "a financial investor with a long-term view, making sure we can carry this [program] as far as we want, really, into the future" research on tetrahydrobiopterin (BH4) as it relates to chronic pain and inflammation.Cambridge, Mass.-based Quartet snagged a final $6.25 million for a total of $23.25 million, drawing three new backers, including Remeditex Ventures LLC and a pair of undisclosed Shanghai-based funders.